British Journal of Dermatology

Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years

Retrieved on: 
Friday, October 20, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Almirall, Lilly, Eli Lilly and Company, AD, Aes, Eli Lilly, Adherence, Conference, Maintenance, Addiction severity index, Conditional sentence, IGA, Shingles, Abstract, The New England Journal of Medicine, Conjunctivitis, British Journal of Dermatology, Atopic dermatitis, Patient, Pharmaceutical industry, Dermatology, Tree-adjoining grammar, EASI

In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.

Key Points: 
  • In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.
  • The most common side effects of lebrikizumab were conjunctivitis, injection site reactions and shingles (herpes zoster).
  • “Results from ADjoin reinforce the strong efficacy and safety profile of lebrikizumab seen in the other Phase 3 atopic dermatitis trials.
  • Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

Retrieved on: 
Thursday, May 11, 2023
Dostarlimab, Docetaxel, GSK, Autoimmunity, Therapy, ISID, The New England Journal of Medicine, CD122, G&A, Atopic dermatitis, NSCLC, Inflammation, BTLA, IGA, Patient, Investment, FIRST, International Society for Infectious Diseases, SAN, Annual general meeting, Webcast, British Journal of Dermatology, GPP, R, PD-1, Research, Rheumatoid arthritis, Immunoglobulin G, Vaccine, Pharmaceutical industry, Broadcasting, Cryptocurrency, Dermatology

“We’re excited about our progress as we continue to develop best-in-class antibodies across a number of high-value immune cell modulatory targets.

Key Points: 
  • “We’re excited about our progress as we continue to develop best-in-class antibodies across a number of high-value immune cell modulatory targets.
  • Collaboration revenue was $1.4 million for the three months ended March 31, 2023, compared to $1.0 million for the three months ended March 31, 2022.
  • The change is due to increased royalties recognized for sales of JEMPERLI and Zejula in the first quarter of 2023.
  • The G&A non-cash, stock-based compensation expense was $6.1 million for the three months ended March 31, 2023 and 2022.

Nogra Pharma announces out-licensing agreement with Torii Pharmaceutical for Japan for New Chemical Entity topical acne treatment

Retrieved on: 
Thursday, January 26, 2023
Standard of care, Prevalence, Journal of the American Academy of Dermatology, NCE, British Journal of Dermatology, New chemical entity, Therapy, Keratinocyte, Skin, Patient, EudraCT, Acne, Nogra, Epidemiology, Adolescence, IGA, Medical device, Pharmaceutical industry, Dermatology

Under the agreement, [for which financial terms are not being disclosed], Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan.

Key Points: 
  • Under the agreement, [for which financial terms are not being disclosed], Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan.
  • NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of the peroxisome proliferation-activated receptor γ (PPARγ), which has been developed by Nogra Pharma in a gel formulation, ideal for topical treatment of acne vulgaris.
  • Leopoldo Zambeletti, Director of Nogra Pharma Ltd, commented: “The agreement with Torii Pharmaceuticals is a testament to the high quality of our scientific network and our development and formulation expertise.
  • Given the promising clinical data, we are confident that NAC-GED-0507 will provide a new treatment option for acne patients.

Nogra Pharma announces out-licensing agreement with Torii Pharmaceutical for Japan for New Chemical Entity topical acne treatment

Retrieved on: 
Thursday, January 26, 2023
Standard of care, Prevalence, Journal of the American Academy of Dermatology, NCE, British Journal of Dermatology, New chemical entity, Therapy, Keratinocyte, Skin, Patient, EudraCT, Acne, Nogra, Epidemiology, Adolescence, IGA, Medical device, Pharmaceutical industry, Dermatology

Under the agreement, [for which financial terms are not being disclosed], Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan.

Key Points: 
  • Under the agreement, [for which financial terms are not being disclosed], Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan.
  • NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of the peroxisome proliferation-activated receptor γ (PPARγ), which has been developed by Nogra Pharma in a gel formulation, ideal for topical treatment of acne vulgaris.
  • Leopoldo Zambeletti, Director of Nogra Pharma Ltd, commented: “The agreement with Torii Pharmaceuticals is a testament to the high quality of our scientific network and our development and formulation expertise.
  • Given the promising clinical data, we are confident that NAC-GED-0507 will provide a new treatment option for acne patients.

LEO Pharma Announces British Journal of Dermatology Publication of Adbry™ (tralokinumab-ldrm) Pooled Safety Data in Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Wednesday, October 26, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Inactivated vaccine, Breast milk, Communication, Disease, Atopic dermatitis, Syringe, Development, Skin, Journal of the American Academy of Dermatology, Allergy, DPT vaccine, Vaccine, Society, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tell, Patient, NOS, AES, Food, Anaphylaxis, Publishing, British Journal of Dermatology, BAD, Wiley (publisher), Association, Leo Pharma, Wiley, Adult, Safety, LEO, Dermatitis, AD, Vitamin, British Association of Dermatologists, Disease management, Hypersensitivity, TCS, Itch, Tralokinumab, FDA, Pharmaceutical industry, Dietary supplement, Health insurance, Birth control, Dermatology, Dermatology

Our ongoing clinical program continues to reveal new learnings and insights on the safety profile of Adbry.

Key Points: 
  • Our ongoing clinical program continues to reveal new learnings and insights on the safety profile of Adbry.
  • Safety remains a top priority for people with moderate-to-severe atopic dermatitis and the clinicians who treat them, as well as for LEO Pharma.
  • Adbry is approved for adult patients whose disease is not adequately controlled with topical prescription therapies or when those are not advisable.
  • The British Journal of Dermatology is owned by British Association of Dermatologists (BAD), the central association of practising UK dermatologists.

Galderma to Highlight Latest Science and Innovation Across Its Product Portfolio at the 2022 AAD Annual Meeting

Retrieved on: 
Friday, March 25, 2022
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Bajaj Consumer Care, PN, Population, AD, AAD, Skin, Geography, Atopic dermatitis, Dermatology, British Journal of Dermatology, Prevalence, Safety, Epidemiology, Prurigo, Systematic review, Prurigo nodularis, Patient, Partnership, Vaccine, Pharmaceutical industry, Aesthetics

Atopic dermatitis (AD) is a chronic, debilitating inflammatory skin disease, characterized by diffuse skin lesions and constant, severe disruptive itch.

Key Points: 
  • Atopic dermatitis (AD) is a chronic, debilitating inflammatory skin disease, characterized by diffuse skin lesions and constant, severe disruptive itch.
  • [4]
    Prurigo nodularis (PN) is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated intense unrelenting itch.
  • [6]
    The global prevalence of PN is not well known as there are few studies describing the epidemiology of the condition.
  • In the U.S., the latest estimate is that PN affects 52.9 people in every 100,000.

Galderma Launches TWYNEO® Cream, the First Ever Tretinoin and Benzoyl Peroxide Combination to Treat Facial Acne

Retrieved on: 
Friday, March 25, 2022
Cream, Bajaj Consumer Care, Angioedema, Tanning, Hives, Association, Red, Exfoliation, Nasdaq, OTC, Acne, BurNIng, Facial, Pain, Abrasion, Dermatitis, View, Parent, Person, Stinger, Tretinoin, Erythema, Surge arrester, Anaphylaxis, Customer experience, Multimedia, AAD, Benzoyl peroxide, Press release, Sol–gel process, Irritation, American Academy of Dermatology, Physical, Pimple, American Academy, FDA, Patient, Partnership, FAAD, Marketing, Dry, Itch, British Journal of Dermatology, Skin, BPO, Epidemiology, Depression, Sunburn, Photosensitivity, Online shopping, Birth control, Sulfur, Cosmetics, MD, Dermatology, Galderma, Q2, Aesthetics

"TWYNEO Cream may help teens with acne especially the boys struggling with generic tretinoin or adhering to complex treatment routines, since it's a once-daily, potent combination that can be used any time of day."

Key Points: 
  • "TWYNEO Cream may help teens with acne especially the boys struggling with generic tretinoin or adhering to complex treatment routines, since it's a once-daily, potent combination that can be used any time of day."
  • A month's supply of TWYNEO Cream costs $0 for commercially covered patients or $60 for uninsured patients with the Galderma CAREConnect savings card.
  • TWYNEO Cream may cost less than generic tretinoin alone when using the Galderma CAREConnect savings card.
  • Indication:TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.

Galderma Launches TWYNEO® Cream, the First Ever Tretinoin and Benzoyl Peroxide Combination to Treat Facial Acne

Retrieved on: 
Friday, March 25, 2022
Cream, Bajaj Consumer Care, Angioedema, Tanning, Hives, Association, Red, Exfoliation, Nasdaq, OTC, Acne, BurNIng, Facial, Pain, Abrasion, Dermatitis, Parent, Person, Stinger, Tretinoin, Erythema, Surge arrester, Anaphylaxis, Customer experience, AAD, Benzoyl peroxide, Press release, Sol–gel process, Irritation, American Academy of Dermatology, Physical, Pimple, American Academy, FDA, Patient, Partnership, FAAD, Marketing, Dry, Itch, British Journal of Dermatology, Skin, BPO, Epidemiology, Depression, Sunburn, Photosensitivity, Flour, Birth control, Sulfur, Cosmetics, MD, Dermatology, Galderma, Q2, Aesthetics

FORT WORTH, Texas, March 25, 2022 /PRNewswire/ -- Galderma announced today the U.S. launch of TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% at the American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022, in Boston, Massachusetts. TWYNEO Cream is the first and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination proven to rapidly treat moderate to severe facial acne.1,2 Patented microencapsulation technology unites two ingredients that have not been previously combined and enables their controlled release to deliver visible results in as little as two weeks.2-4

Key Points: 
  • "TWYNEO Cream may help teens with acne especially the boys struggling with generic tretinoin or adhering to complex treatment routines, since it's a once-daily, potent combination that can be used any time of day."
  • A month's supply of TWYNEO Cream costs $0 for commercially covered patients or $60 for uninsured patients with the Galderma CAREConnect savings card.
  • TWYNEO Cream may cost less than generic tretinoin alone when using the Galderma CAREConnect savings card.
  • Indication:TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.